Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chad,
Thank you for all of your efforts. Best of luck with your new endeavors!
I've received mine from TradeKing and eTrade. US investor though...
Not sure what the intent of his statement is... Unfortunately, I don't read Swedish.
Here is the same article, but with the Microsoft translation
I'm not sure if this has been posted or not...
It appears to be a publication of an email that Nisse Sandberg sent out to JF members.
Swedish Version
Google-Translated English Version
They are looking to have it in place by Jan 31st.
Are there rules precluding them from purchasing via the open market?
They have certainly deviated from one normal mode of operation (regular PR's) in the past couple months, why not another?
Thanks
Given the fact that the company has a history of repurchasing shares and the fact that they have been silent for this long, I have to wonder if allowing the share price to dwindle isn't intentional?
Since they are generating more and more revenue by the day as their operations ramp up, selling shares (in Q411, Q112, and early Q212 when prices were favorable) then planning on allowing the share price to be depressed through the 'summer' while they backstop the bid as prices fall might be a good way to minimize dilution. (I know, I'm really reaching!)
Any thoughts?
Hopefully they will eventually get around to being DTC eligible again someday soon. It would make them a little more "shareholder friendly"...
There are many trading platforms that cannot buy/sell UBRG. (like mine... Zecco)
Yes. I'm seeing the "Green & Natural Agriculture for the 21st Century" slide.
I was getting the message that the conference had not yet begun, but now I'm getting invalid conf code...
Tried the original that you had posted, and it works now.
1-404-920-6604
486548
AnyName
Try using:
Conference Dial-In: 1-404-920-6604
Conference Code: 486548
Screen Name: YourName
Authorized Shares will be reduced as well per CC
Agreed! No reverse split is needed (or wanted). Let the company continue to execute their business plan. The share price will eventually take care of itself.
You can add my 110k to your list... Thanks
Advanced Cell Technology and CHA Biotech Cross Oceans in Hopes of Curing Blindness
http://www.onlineprnews.com/news/155163-1311004797-advanced-cell-technology-otcactc-and-cha-biotech-cross-oceans-in-hopes-of-curing-blindness.html
Online PR News – 18-July-2011 –Written By
Devon Chandler Blake, Ph.D.
Don W Kukkido
Advanced Cell Technology (OTC:ACTC), a Massachusetts-based biotechnology leader in the field of regenerative medicine, has crossed the frontier by initiating the first human stem cell trials last week for Stargardt’s Macular Dystrophy (SMD). And across the world, the CHA Stem Cell Institute in Seoul, Korea, through a licensing agreement with ACT, will begin its own human trials within the week using ACT’s hRPE (human retinal pigment epithelial cells) for SMD and the more widely-spread adult type of age related macular degeneration (AMD).
Central to any human drug trial is the hope of biotech companies to acquire Orphan Drug status (granted for drugs which treat rare diseases) and future compassionate use designation (off-label use for severely vulnerable individuals), both of which ACT and CHA have acquired or will shortly. Orphan Drug designation speeds the trial phases while offering the further protection of exclusivity and the opportunity to add many off-label uses of the drugs, ensuring a broader and more significant market.
With these issues in mind and in large part through his association with the www.investorstemcell.com group, a nonpartisan organization which disseminates information about stem cell research and developments on their popular website, InvestorStemCell.com, free-lance writer Don W. Kukkido requested and was granted a rare personal interview with Dr. Kwang Yul Cha, President and Chairman of CHA Biotech. Anticipating groundbreaking progress from the human trials being conducted by ACT and soon by CHA, Kukkido met with Dr. Cha on July 12th in Gangnam-gu, South Korea.
During the interview Dr. Cha confirmed that CHA Stem Cell Institute will soon inject their first patients with ACT’s hRPE stem cells and, as in the ACT trials, expects initial results in six weeks or less. Cha added that "safety and efficacy standards at his company are equal to and in line with the standards of the US-based, Advanced Cell Technology." Since the United States FDA has already approved the IND (investigational new drug) for cells used in the trials for Stargardt's (MA09-hRPE) and thus their safety for humans, the Safety Phase of the trials will be limited and thus should that of the larger trial in Korea for age related macular degeneration (AMD) using the same hRPE cells.
While Cha will use ACT data, he will also employ his own and offer the findings for required KFDA review. With successful trial results expected, Cha commented, "he would terminate Phase I/II and move faster into Phase III in combination with commercialization." He anticipates that after administering the first immunosuppressant’s and injecting hRPE cells two weeks later he can then reevaluate the strengths and dosages within two months and determine the precise amount of stem cells needed to achieve optimal results for future procedures. Presently applying for Orphan Drug status and further designation for compassionate use, Cha feels KFDA decision could come within a week. However, his main thrust concerns trial completion and moving forward into marketing the myriad off-label uses for over 200 retinal diseases.
More than diseases of the eye, however, are central to the research and development efforts at the CHA Stem Cell Institute. Owing to another licensing agreement with Massachesetts-based Advanced Cell Techology, CHA is building a manufacturing plant to create blood, platelets, and bone marrow under the ACT Hemangioblast Program. Dr. Robert Lanza, head medical researcher at ACT, discovered that hemangioblasts, which are multipotent cells, can be differentiated into the full spectrum of blood cells and can be manufactured in the lab setting, thus obviating the problems with rejection or type matching.
The market for this technology is limitless, and Dr. Cha intends to move forward with KFDA approval by 2013 but stated " it’s still too early to decide whether to use the Red Cross for distribution and marketing." He added that he will build manufacturing plants wherever he sees the need, from the United States, South America, Europe, to Asia—and that he has twenty teams of researchers ready to begin work on whatever is developed first. To supplement these already herculean efforts, Cha has additional teams working on Alzheimer’s Disease and Parkinson’s and will start trials with three patients over an 18-month period, again stating that if these trials also proceed well, he can move ahead to Phase III with minimal effort.
Kukkido asked Dr. Cha, who further plans human cardiovascular trials in 2013 and 2014, if he will use the Single Blastomere technology developed and patented by ACT for harvesting stem cells without damaging embryos. He confirmed this and added that their own Dr. Chung Hyung-Min was one of the developers of the technology.
Finally, Dr. Cha requested that Wortman thank InvestorStemCell.com for helping to set the record straight about his company and for serving as the premier source for disseminating information about advancements in stem cells through its website, InvestorStemCell.com. Sai Rosen Director of Client Services for InvestorStemCell.com commented "ACT and CHA alone offer proof that the exponentially growing field of stem cell research and development is not the stuff of science fiction set in the future but a current reality with limitless potential."
Disclosure: Stem Cell Media, LLC. nor any of its Companies has been compensated for this article.
It is working for me after a little trial and error...
I used:
1.404.920.6440
71483493#
Florinda:
That is exactly how I understand the situation, but I am certainly not an expert on SEC rules and regulations.
As I understand it, they are able to provide news of material events and regular filings. However, they cannot speculate in regards to forward-looking projections or possibilities.
The dividend was posted to my account on 10/15/2010...
http://finance.yahoo.com/news/Sino-Agro-Food-Inc-Receives-bw-1135831855.html?x=0&.v=1
Press Release Source: Sino Agro Food, Inc. On Thursday October 21, 2010, 10:15 am EDT
GUANGZHOU, China--(BUSINESS WIRE)-- Sino Agro Food, Inc. (Pink Sheet: SIAF), an emerging integrated, diversified agriculture technology and organic food company with subsidiaries operating in China, is pleased to announce the results of a recent meeting with HuangYuan government officials as well as provide an update on current projects under construction.
In a recent meeting of Qinghai and HuangYuan government officials in China, the government officially recognized in writing the importance of SanJiang A Power’s project enzyme, bio-organic fertilizer, livestock feed and modern cattle housing operations to its overall regional agricultural development. One of the central committees goals was to, “vigorously support the industrialization of agriculture leading companies; enhance the quality characteristics of the local agricultural and livestock products; make the leading companies become a force for the development of the rural economy”. As a result, the Company will now qualify for additional government grants that will match dollar for dollar investments made by Sino Agro Food starting in 2011.
To date, the HuangYuan government has provided grants totaling RMB 900,000 as well as provided infrastructure support and construction valued at approximately RMB 1,500,000 for the SanJiang, HuangYuan joint venture project.
Construction continues at the SanJiang, HuangYuan joint venture project with the office building now reaching its second floor of construction. The joint venture is also expecting the arrival of its first 120 head of cattle by the end of October. The joint venture has fully booked its sales of 10,000 MT of fertilizer for 2010 with sales prices coming in 20% higher than expected. Feedstock crop harvest averaged 3 MT per MU, which was slightly lower than expected due to previous heavy rains washing out some areas however gains in other business will keep overall revenue at previous estimates.
I picked up 1092 @ 1.19 on 12/8...
Thanks for sharing!
http://www.thestreet.com/story/10936305/2/13-stock-picks-for-2011.html
Excerpt:
"Sino Agro Food (SIAF) has institutional interest even though it trades on the PINK sheets because they consistently deliver on their promises so far."
Still holding as well...
Thanks for the summary.
Would someone summarize the video from Fox News? I can't get any FoxNews videos to play...
Who was named CEO after Paul?
Thanks!
Oh, please do show me something... like how to lose $30k, whine and complain, blame your lack of patience on supposedly misleading PR's, try to strong-arm the company for hush money, and then when all else fails... sue someone.
Sino Agro is a rapidly growing company with many irons in the fire. Missing a soft deadline here and there is to be expected. All companies, especially rapidly growing ones miss deadlines. That is part of the risk of investing in them. Perhaps you should stick with more stable companies like JnJ/MCD.
Without a doubt, he is guilty of extortion (and should be prosecuted)... Given the fact that he has publicly admitted this several times, I can't imagine it would take much work to prosecute.
With his recent post about buying shares, his ulterior motives are clearly showing. It is unfortunate that the SEC(no evil) is such a joke.
Sounds like you should be charged with extortion...
"why these guys won't peacefully pay the $30K in losses due to past false and misleading statements I demanded is beyond me. Once the lawsuit is filed, that $30K turns into mega bucks and frankly, I think that SIAF management thinks I was bluffing all along, but they're sadly mistaken. Their refusal will ultimately turn out to be one of the dumbest moves that such a promising company could ever make."
Extortion: (http://en.wikipedia.org/wiki/Extortion)
Extortion, outwresting, and/or exaction is a criminal offense which occurs when a person unlawfully obtains either money, property or services from a person(s), entity, or institution, through coercion. Refraining from doing harm is sometimes euphemistically called protection. Extortion is commonly practiced by organized crime groups. The actual obtainment of money or property is not required to commit the offense. Making a threat of violence which refers to a requirement of a payment of money or property to halt future violence is sufficient to commit the offense. Exaction refers not only to extortion or the unlawful demanding and obtaining of something through force,[1] but additionally, in its formal definition, means the infliction of something such as pain and suffering or making somebody endure something unpleasant.
Neither extortion nor blackmail require a threat of a criminal act, such as violence, merely a threat used to elicit actions, money, or property from the object of the extortion. Such threats include the filing of reports (true or not) of criminal behavior to the police, revelation of damaging facts (such as pictures of the object of the extortion in a compromising position), etc.
I have a question regarding the dividend rumors... Is there a dividend planned or voted upon? Have the results of the shareholder vote been released? Is the dividend for the common stock or just preferred?
Thanks in advance for any clarification anyone can provide.